“Drug resistance is the single most important cause of cancer treatment failure and carries a massive burden to patients, healthcare providers, drug developers and society. It is estimated that Multidrug Resistance (MDR) plays a major role in up to 50% of cancer cases.”
Cancer Drug Resistance
Rescue Therapeutics has seen signals of efficacy in in vitro and/ in vivo studies for several types of cancers and in synergy with many chemotherapy agents. Our most advanced work, however is for second-line ovarian cancer patients and patients with Non-Hodgkin’s lymphoma. Our in vivo studies in both areas have shown dramatic efficacy when RTI-79 is given in conjunction with doxorubicin or DOXIL®. Most recently we have also seen significant results in in vitro models of triple negative breast cancer.
For more about our most advanced results, click here: